|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.98 USD | +1.16% |
|
+4.33% | +13.27% |
| 06-30 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +68.62% | 12 | ||||||
| 822.48 | +24.08% | 28 | ||||||
| 287.95 | +15.78% | 19 | ||||||
| 2,056,533.8 | +50.88% | 24 | ||||||
| 96.64 | +12.47% | 16 | ||||||
| 222.83 | +11.22% | 31 | ||||||
| 47.89 | -35.1% | 19 | ||||||
| 111.45 | -4.95% | 22 | ||||||
| 102.06 | +36.43% | 25 | ||||||
| 485.42 | +2.54% | 12 | ||||||
| 102.47 | +30.82% | 22 | ||||||
| 276.56 | +12.62% | 21 | ||||||
| 87.69 | +46.77% | 26 | ||||||
| 458,000 | +46.09% | 5 | ||||||
| 349.78 | -6.83% | 9 | ||||||
| - | - | 61.5 | +22.75% | 1 | ||||
| 14.4 | +59.95% | 12 | ||||||
| 30.05 | +95.67% | 9 | ||||||
| 77.7 | -13.07% | 10 | ||||||
| 72.5 | +15.35% | 2 | ||||||
| Average | 125,890.82 | +24.60% | 16 | ||||||
| Weighted average by Cap. | 218,970.36 | +18.93% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
